Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2013

View Archived Issues

HE-400 affects multiple pathways linked to IBS

Novel FabI inhibitors active against resistant S. aureus

Flatley Discovery Lab nominates drug candidate for cystic fibrosis

Starpharma's dendrimer-enhanced oxaliplatin shows reduced neurotoxicity in mouse model

Microbiotix describes activity of antibacterials with dual mechanism of action

Efficacy seen with PEG-rHuPH20 plus gemcitabine in pancreatic cancer

Preclinical studies with GLV-1h68 in sarcoma lead to phase I clinical trial

Hepatitis A virus cellular receptor has prognostic significance in breast cancer

German and Swiss team presents novel carbohydrate-based vaccines

Roche discloses new agents for hepatitis B virus infection

Scientists at Bayer Healthcare patent novel Mnk1 inhibitors

Daiichi Sankyo synthesizes new EP2 inhibitors

Novel gp41 peptide mimetics for HIV infection

Amarantus BioScience reports analytical performance data for the LymPro Test

DiaGenic provides update on two diagnostic tests for AD

University Health Network plans phase I safety and pharmacokinetic study of CFI-400945

Berg and Icahn School of Medicine form pharmaceutical and diagnostic R&D partnership

QRxPharma expands MoxDuo agreement with Aspen Pharmacare

Medical Developments submits MAA in Europe for penthrox

Symphogen and OMT collaborate to develop novel therapeutic candidates

OncoCyte enters collaboration with Wistar Institute to develop cancer diagnostics

KineMed and Amgen enter agreement to develop kinetic biomarkers

Enrollment completed in phase II Arikace study in NTM lung disease

Reversal of anticoagulation effect of factor Xa inhibition seen with andexanet alfa

Cel-Sci and Ergomed sign deal for Multikine

Atterocor gains orphan drug status for ATR-101, initiates clinical program in ACC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...